86826-91-7

Upstream product

• 203314-50-5 (2-Bromo-5-methoxy-phenyl)-acetyl chloride 
• 86826-93-9 2-(2-bromo-5-methoxyphenyl)acetic acid 
• 1798-09-0 m-methoxyphenylacetic acid 
• 86826-94-0 N-<2-(3,4-Methylenedioxyphenyl)ethyl>-2'-bromo-5'-methoxyphenylacetamide 

Downstream Products

• 81531-49-9 erythro/threo-1-(2'-Bromo-5'-methoxy-α-hydroxybenzyl)-2-methyl-1,2,3,4-tetrahydro-6,7-methylenedioxyisoquinoline 
• 86826-89-3 erythro/threo-1-(2'-Bromo-5'-methoxy-α-hydroxybenzyl)-1,2,3,4-tetrahydro-6,7-methylenedioxyisoquinoline 
• 81531-48-8 1-(2'-Bromo-5'-methoxybenzoyl)-2-methyl-3,4-dihydro-6,7-methylenedioxyisoquinolium iodide 
• 86826-92-8 1-(2'-Bromo-5'-methoxybenzoyl)-3,4-dihydro-6,7-methylenedioxyisoquinoline 

Relevant academic research and scientific papers

In vitro functional evaluation of isolaureline, dicentrine and glaucine enantiomers at 5-HT2 and α1 receptors

Compounds with activity at serotonin (5-hydroxytryptamine) 5-HT2 and α1 adrenergic receptors have potential for the treatment of central nervous system disorders, drug addiction or overdose. Isolaureline, dicentrine and glaucine enantiomers were synthesized, and their in vitro functional activities at human 5-HT2 and adrenergic α1 receptor subtypes were evaluated. The enantiomers of isolaureline and dicentrine acted as antagonists at 5-HT2 and α1 receptors with (R)-isolaureline showing the greatest potency (pKb?=?8.14 at the 5-HT2C receptor). Both (R)- and (S)-glaucine also antagonized α1 receptors, but they behaved very differently to the other compounds at 5-HT2 receptors: (S)-glaucine acted as a partial agonist at all three 5-HT2 receptor subtypes, whereas (R)-glaucine appeared to act as a positive allosteric modulator at the 5-HT2A receptor.

Synthetic Photochemistry: Synthesis of (+/-)-Oliveridine

The first synthesis of (+/-)-oliveridine (9b) and (+/-)-epioliveridine (9a) are described.The key steps are:(i) preparation of N--2'-bromo-5'-methoxyphenylacetamide (4), its Bischler-Napieralski cyclisation followed by m